[VIEW] agent=Environmental Services (EVS) Operations Manager | scenario_id=112 | rounds=20

--- Round 0 ---
[R0.1] Infection Prevention & Control (IPC) Director (speak, public): Good morning, everyone. As we all know, our hospital-onset CDI rate is currently at 9.8 per 10,000 patient-days, significantly higher than our goal of 6.0. I'd like to discuss a 60-day remediation plan to address this issue. Let's start by understanding our current cleaning performance and the feasibility of implementing any changes. Can you both share your initial thoughts and any relevant information?
[R0.2] Environmental Services (EVS) Operations Manager (speak, public): Our current cleaning performance metrics show a median terminal clean cycle time of 62 minutes per discharge, slightly above our target of 55 minutes. We're also seeing a disinfectant dwell-time adherence rate of 54% on 80 timed audits, with a required contact time of 10 minutes. Additionally, our ATP surface testing for high-touch areas has a pass rate of 76% from 320 swabs, with a threshold of 250 RLU. Lastly, our EVS staff have completed 78% of the training for the updated enteric protocol, with a deadline of March 31, 2026. I'd like to understand how these metrics align with the infection-control outcomes we're trying to achieve and what adjustments are being considered.
[R0.3] Supply Chain Contracting Director (speak, public): We've been using QuatClean Plus across all four hospitals, with an annual spend of $312,000. If we decide to switch to sporicidal wipes, our monthly spend is estimated to increase by $28,000 at current usage levels. The supplier has a capacity of 3,500 canisters per week and a lead time of 14 days. I'd like to understand the clinical rationale behind considering a switch to sporicidal wipes and how it aligns with the proposed 60-day remediation plan.

--- Round 1 ---
[R1.1] Infection Prevention & Control (IPC) Director (speak, public): Thank you both for the valuable insights. EVS Operations Manager, the metrics you've shared are quite helpful. The median terminal clean cycle time and disinfectant dwell-time adherence rate are particularly important. I'd like to focus on improving the dwell-time adherence rate as it directly impacts the effectiveness of our disinfection process. Supply Chain Contracting Director, regarding the potential switch to sporicidal wipes, our consideration is driven by the need for a more effective disinfectant against C. difficile spores. The current product, QuatClean Plus, may not be sufficient given our high CDI rate. Can you elaborate on the contractual implications of switching products and the potential lead times we should be aware of?
[R1.2] Environmental Services (EVS) Operations Manager (speak, public): To improve dwell-time adherence, we'll need to intensify our training and monitoring efforts. I'd like to know more about the proposed adjustments to our cleaning protocols and how they will be measured. Additionally, understanding the budget impact and supply reliability of switching to sporicidal disinfectants is crucial for planning. Are there any specific contractual constraints or penalties we should be aware of when considering a product switch?
[R1.3] Supply Chain Contracting Director (speak, public): To address the contractual implications, we currently have a contract for QuatClean Plus with an annual spend of $312,000. If we switch to sporicidal wipes, we'll need to consider the contract exit penalty and negotiate a new contract. The supplier for sporicidal wipes has a capacity of 3,500 canisters per week and a lead time of 14 days, which is relatively stable. However, I need to understand the expected demand stability and any potential allocation risks. I'd like to know more about the proposed implementation timeline and how it aligns with the 60-day remediation plan.

--- Round 2 ---
[R2.1] Infection Prevention & Control (IPC) Director (speak, public): To align with the 60-day remediation plan, we need to finalize our strategy on improving dwell-time adherence and potentially switching to sporicidal wipes. EVS Operations Manager, can you estimate the additional resources or training required to improve dwell-time adherence to at least 80%? Supply Chain Contracting Director, can you confirm if there are any contractual exit penalties for our current QuatClean Plus contract and provide a detailed breakdown of the costs associated with switching to sporicidal wipes?
[R2.2] Environmental Services (EVS) Operations Manager (speak, public): To improve dwell-time adherence to at least 80%, we will need to intensify our training efforts and potentially adjust our staffing levels during peak discharge times. I estimate we will need additional resources for training and potentially some overtime to ensure coverage. Regarding the current training completion rate of 78% for the updated enteric protocol, we are on track to meet the March 31, 2026 deadline, but accelerating this process could help us achieve the 60-day remediation goal. I'd like to understand the budget implications and supply reliability of switching to sporicidal wipes to ensure we can implement the changes effectively.
[R2.3] Supply Chain Contracting Director (speak, public): To address the budget implications and supply reliability of switching to sporicidal wipes, I can confirm that our current annual spend on QuatClean Plus is $312,000. Switching to sporicidal wipes is estimated to increase our monthly spend by $28,000 at current usage levels. The supplier has a capacity of 3,500 canisters per week and a lead time of 14 days. However, I'd like to understand the expected demand stability and any potential allocation risks better. Infection Prevention & Control (IPC) Director, can you provide more details on the expected usage patterns of sporicidal wipes across the four hospitals? Additionally, EVS Operations Manager, have you identified any potential operational challenges or hotspots that could impact the implementation of sporicidal wipes within the proposed 60-day remediation timeline?

--- Round 3 ---
[R3.1] Infection Prevention & Control (IPC) Director (speak, public): To finalize our 60-day remediation plan, let's summarize the key points discussed. EVS Operations Manager, you've highlighted the need for intensified training and potential staffing adjustments to improve dwell-time adherence. Supply Chain Contracting Director, you've outlined the budget implications and supply reliability of switching to sporicidal wipes. I propose we move forward with a phased implementation: first, intensifying training and monitoring for dwell-time adherence; second, assessing the feasibility of switching to sporicidal wipes based on the contractual and budgetary analysis. Let's aim to have a detailed plan by the end of the week, incorporating the insights from both of you. EVS Operations Manager, can you provide a draft on the training and staffing adjustments by tomorrow? Supply Chain Contracting Director, please provide a detailed cost analysis and contractual implications for the product switch by the same timeline.
[R3.2] Environmental Services (EVS) Operations Manager (speak, public): I can provide a draft on the training and staffing adjustments by tomorrow. To improve dwell-time adherence to at least 80%, we will need to intensify our training efforts and potentially adjust our staffing levels during peak discharge times. I'll outline the specific resources required and the plan to accelerate our training completion for the updated enteric protocol. Additionally, I'll highlight any operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline.
[R3.3] Supply Chain Contracting Director (speak, public): I can provide a detailed cost analysis and contractual implications for switching to sporicidal wipes by tomorrow. To ensure a smooth transition, I'll need to confirm the expected demand stability and understand any potential allocation risks. Infection Prevention & Control (IPC) Director, can you provide more details on the expected usage patterns of sporicidal wipes across the four hospitals? Additionally, EVS Operations Manager, have you identified any potential operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline?

--- Round 4 ---
[R4.1] Infection Prevention & Control (IPC) Director (speak, public): Thank you both for your commitments to provide the necessary details by tomorrow. To ensure we're aligned, let's confirm that our 60-day remediation plan will include intensified training and monitoring for dwell-time adherence, as well as a thorough assessment of switching to sporicidal wipes. Supply Chain Contracting Director, please confirm if there are any contractual exit penalties for our current QuatClean Plus contract. EVS Operations Manager, please highlight any operational challenges or hotspots that could impact the implementation within the proposed timeline. Let's reconvene tomorrow to review your submissions and finalize the plan.
[R4.2] Environmental Services (EVS) Operations Manager (speak, public): I will provide a draft on the training and staffing adjustments by tomorrow. To improve dwell-time adherence to at least 80%, we will need to intensify our training efforts and potentially adjust our staffing levels during peak discharge times. I'll outline the specific resources required and the plan to accelerate our training completion for the updated enteric protocol. Additionally, I'll highlight any operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline.
[R4.3] Supply Chain Contracting Director (speak, public): I will provide a detailed cost analysis and contractual implications for switching to sporicidal wipes by tomorrow. To ensure a smooth transition, I'll need to confirm the expected demand stability and understand any potential allocation risks. Infection Prevention & Control (IPC) Director, can you provide more details on the expected usage patterns of sporicidal wipes across the four hospitals? Additionally, EVS Operations Manager, have you identified any potential operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline?

--- Round 5 ---
[R5.1] Infection Prevention & Control (IPC) Director (speak, public): Let's reconvene tomorrow to review the drafts from both of you and finalize our 60-day remediation plan. Please ensure that the documents include all the necessary details we've discussed, such as training and staffing adjustments, cost analysis, and contractual implications. I'm looking forward to seeing a comprehensive plan that aligns with our objectives.
[R5.2] Environmental Services (EVS) Operations Manager (speak, public): I will provide a draft on the training and staffing adjustments by tomorrow, as requested. To improve dwell-time adherence to at least 80%, we will need to intensify our training efforts and potentially adjust our staffing levels during peak discharge times. I'll outline the specific resources required and the plan to accelerate our training completion for the updated enteric protocol. Additionally, I'll highlight any operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline.
[R5.3] Supply Chain Contracting Director (speak, public): I will provide a detailed cost analysis and contractual implications for switching to sporicidal wipes by tomorrow. To ensure a smooth transition, I'll need to confirm the expected demand stability and understand any potential allocation risks. Infection Prevention & Control (IPC) Director, can you provide more details on the expected usage patterns of sporicidal wipes across the four hospitals? Additionally, EVS Operations Manager, have you identified any potential operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline?

--- Round 6 ---
[R6.1] Infection Prevention & Control (IPC) Director (speak, public): Let's reconvene tomorrow to review the drafts from both of you and finalize our 60-day remediation plan. Please ensure that the documents include all the necessary details we've discussed, such as training and staffing adjustments, cost analysis, and contractual implications. I'm looking forward to seeing a comprehensive plan that aligns with our objectives.
[R6.2] Environmental Services (EVS) Operations Manager (speak, public): I will provide a draft on the training and staffing adjustments by tomorrow, as requested. To improve dwell-time adherence to at least 80%, we will need to intensify our training efforts and potentially adjust our staffing levels during peak discharge times. I'll outline the specific resources required and the plan to accelerate our training completion for the updated enteric protocol. Additionally, I'll highlight any operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline.
[R6.3] Supply Chain Contracting Director (speak, public): I will provide a detailed cost analysis and contractual implications for switching to sporicidal wipes by tomorrow. To ensure a smooth transition, I'll need to confirm the expected demand stability and understand any potential allocation risks. Infection Prevention & Control (IPC) Director, can you provide more details on the expected usage patterns of sporicidal wipes across the four hospitals? Additionally, EVS Operations Manager, have you identified any potential operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline?

--- Round 7 ---
[R7.1] Infection Prevention & Control (IPC) Director (speak, public): Let's reconvene tomorrow to review the drafts from both of you and finalize our 60-day remediation plan. Please ensure that the documents include all the necessary details we've discussed, such as training and staffing adjustments, cost analysis, and contractual implications. I'm looking forward to seeing a comprehensive plan that aligns with our objectives.
[R7.2] Environmental Services (EVS) Operations Manager (speak, public): I will provide a draft on the training and staffing adjustments by tomorrow, as requested. To improve dwell-time adherence to at least 80%, we will need to intensify our training efforts and potentially adjust our staffing levels during peak discharge times. I'll outline the specific resources required and the plan to accelerate our training completion for the updated enteric protocol. Additionally, I'll highlight any operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline.
[R7.3] Supply Chain Contracting Director (speak, public): I will provide a detailed cost analysis and contractual implications for switching to sporicidal wipes by tomorrow. To ensure a smooth transition, I'll need to confirm the expected demand stability and understand any potential allocation risks. Infection Prevention & Control (IPC) Director, can you provide more details on the expected usage patterns of sporicidal wipes across the four hospitals? Additionally, EVS Operations Manager, have you identified any potential operational challenges or hotspots that could impact the implementation within the proposed 60-day remediation timeline?

--- Round 8 ---
[R8.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R8.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R8.3] Supply Chain Contracting Director (leave, public): 

--- Round 9 ---
[R9.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R9.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R9.3] Supply Chain Contracting Director (leave, public): 

--- Round 10 ---
[R10.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R10.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R10.3] Supply Chain Contracting Director (leave, public): 

--- Round 11 ---
[R11.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R11.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R11.3] Supply Chain Contracting Director (leave, public): 

--- Round 12 ---
[R12.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R12.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R12.3] Supply Chain Contracting Director (leave, public): 

--- Round 13 ---
[R13.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R13.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R13.3] Supply Chain Contracting Director (leave, public): 

--- Round 14 ---
[R14.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R14.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R14.3] Supply Chain Contracting Director (leave, public): 

--- Round 15 ---
[R15.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R15.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R15.3] Supply Chain Contracting Director (leave, public): 

--- Round 16 ---
[R16.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R16.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R16.3] Supply Chain Contracting Director (leave, public): 

--- Round 17 ---
[R17.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R17.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R17.3] Supply Chain Contracting Director (leave, public): 

--- Round 18 ---
[R18.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R18.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R18.3] Supply Chain Contracting Director (leave, public): 

--- Round 19 ---
[R19.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R19.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R19.3] Supply Chain Contracting Director (leave, public): 

